Discover a science-led approach with unparalleled project delivery.
As a leading Contract, Development and Manufacturing Organisation (CDMO) our defining traits lie in our adaptability and nimbleness.
Through our science-led approach we align to your drug development needs from pre-clinical to late phase manufacture, across oral solid dosage forms, liquids, semi-solids, nasal and inhaled products.
Our team support you at each stage of your drug program lifecycle from pre-clinical to market.
Our CDMO services include formulation development, phase 1, phase 2 and phase 3 clinical supply, process scale-up and optimisation, quality control, analytical development and validation, and registration activities.
Our project teams are made up of subject experts from across our business. With oversight from an Executive Leadership Team member on every project, our approach ensures you can have open and transparent conversations, enabling quick decision-making and collaboration across our business to ensure your project’s success.
Our award-winning 50,000 sqft development and manufacturing facility, Trent Gateway, enables our teams to be flexible and nimble so that we can problem-solve, meet your timescales, and deliver solutions that meet patient targets.
Upperton will apply its expertise to enable the next generation of Adenovirus-vectored vaccines to be delivered without needles.
Discover more about our team. In this Spotlight, meet our Project Coordinator, Sophie Skinner, on her journey with Upperton.
Speak with our team of experts and set up a discovery call to discuss your project in more detail.